0000899243-23-001803.txt : 20230113
0000899243-23-001803.hdr.sgml : 20230113
20230113183336
ACCESSION NUMBER: 0000899243-23-001803
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230113
FILED AS OF DATE: 20230113
DATE AS OF CHANGE: 20230113
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gould Robert J
CENTRAL INDEX KEY: 0001577034
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38978
FILM NUMBER: 23529876
MAIL ADDRESS:
STREET 1: C/O EPIZYME, INC.
STREET 2: 400 TECHNOLOGY SQUARE, 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fulcrum Therapeutics, Inc.
CENTRAL INDEX KEY: 0001680581
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474839948
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-651-8851
MAIL ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-13
0
0001680581
Fulcrum Therapeutics, Inc.
FULC
0001577034
Gould Robert J
C/O FULCRUM THERAPEUTICS, INC.
26 LANDSDOWNE STREET
CAMBRIDGE
MA
02139
1
1
0
0
Interim President & CEO
Common Stock
2023-01-13
4
S
0
6766
15.00
D
499864
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022.
/s/ Greg Tourangeau, as attorney-in-fact for Robert J. Gould
2023-01-13